Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

Author： Molife L.   Rudman Sarah   Alam Salma   Tan Daniel   Kristeleit Hartmut   Middleton Gary   Propper David   Bent Liz   Stopfer Peter   Uttenreuther-Fischer Martina   Wallenstein Gudrun   de Bono Johann   Spicer James  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.72, Iss.6, 2013-12, pp. : 1213-1222

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial

By Becerra Carlos   Salazar Ramon   Garcia-Carbonero Rocio   Thomas Anne   Vázquez-Mazón Federico   Cassidy James   Maughan Tim   Castillo Manuel   Iveson Tim   Yin Donghua   Green Stephanie   Bergsland Emily  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 695-702

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study

By Mross Klaus   Niemann Bernward   Massing Ulrich   Drevs Joachim   Unger Clemens   Bhamra Rupinder   Swenson Christine  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 6, 2004-12 ,pp. : 514-524

Springer Publishing Company

Access to resources Recommend Favorite

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

By Murakami H.   Kurata T.   Onozawa Y.   Watanabe J.   Ono A.   Takahashi T.   Yamamoto N.   Fujisaka Y.   Kiyota H.   Hayashi H.   Tanaka K.   Nakagawa K.   Kuroda S.  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 623-630

Springer Publishing Company

Access to resources Recommend Favorite

Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors

By Freiwald Matthias   Schmid Ulrike   Fleury Angele   Wind Sven   Stopfer Peter   Staab Alexander  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 759-770

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of docetaxel in patients with relapsed and refractory Ewing's Tumours

By Meyer T.   Mctiernan A.   Whelan J.  

Sarcoma, Vol. 7, Iss. 1, 2003-01 ,pp. : 13-17

Informa Healthcare

Access to resources Recommend Favorite